Alzinova announced today the successful outcome of the TO4 warrant exercise, completing the bridging financing package initiated with the rights issue earlier this year. While a strategic partnership is still a necessary long-term funding solution for the planned phase II study of ALZ-101, we view the 94.2% exercise rate as an encouraging outcome that strengthens the company’s financial position, extends its operational runway, and provides additional flexibility in ongoing partnership discussions.
LÄS MER
